XNSE
ZOTA
Market cap480mUSD
Nov 12, Last price
1,532.50INR
Name
Zota Health Care Ltd
Chart & performance
P/E
—
P/S
8.63
EPS
—
Div yield, %
0.07%
Shrs. gr., 5y
6.03%
Rev. gr., 5y
38.22%
Revenues
5.39b
+83.86%
Net income
-739m
L+31.10%
CFO
-790m
L+61.42%
Dividend
Sep 21, 20261 INR/sh
Earnings
Nov 10, 2026
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zota Health Care Limited is an Indian pharmaceutical firm dedicated to the development, manufacturing, and distribution of a broad spectrum of health-related products across India. Its extensive portfolio encompasses generic medications, over-the-counter (OTC) remedies, traditional Ayurvedic formulations, and nutritional supplements (nutraceuticals). The company places a particular emphasis on supplying treatments for various long-term illnesses, including but not limited to heart disease, diabetes, and thyroid conditions. By March 31, 2021, Zota had established a considerable retail network, operating 591 stores under its DAVAINDIA brand name throughout 24 states in India. The company was founded in 1995 and is currently headquartered in Surat, India.
Key people
Ketankumar Zota
Non-Executive Chairman of the Board · since 2010
Viral Mandviwala
Chief Financial Officer
Ashvin Variya
Compliance Officer, Company Secretary
Moxesh Zota
Executive Managing Director · since 2016
Laxmi Sharma
Executive Director · since 2023
Viren Zota
Whole-Time Director, Head of Domestic Market · since 2022
Kamlesh Zota
Executive Whole-time Director · since 2015
Himanshu Zota
Executive Whole-time Director · since 2015
Ratilal Harkhani
Plant Manager · since 2009
Niralkumar Zota
Head of Domestic Market · since 2010
Bhumi Doshi
Non-Executive Independent Director · since 2019
Jayshreeben Mehta
Non-Executive Independent Director · since 2019
Varshabahen Mehta
Non-Executive Independent Director · since 2016
Vitrag Modi
Non-Executive Independent Director · since 2019
Dhaval Patwa
Non-Executive Independent Director · since 2023
Dhiren Shah
Non-Executive Independent Director · since 2019
Valuation
Title INR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||